The Expression Of PChk2-Thr68/pCdc25C-Ser216Proteins And Its Clinical Significance In Breast Cancer

ObjectiveGenomic mutation, deletion and abnormal expression are related to the developmentof cancers, DNA damage repair network cannot repair the abnormal protein in time andmay be one of the reasons for incidence of breast cancer. ATM/CHK2/CDC25C signalpathway plays an important role in DNA damage repair, cell cycle arrest and inducive cellapoptosis by DNA double strand breaks. In this study, we applied the methods ofimmunohistochemistry to detect pCHK2-Thr68and pCDC25C-Ser216protein in breastcancer tissues and analysed the correlation between the expression of pCHK2-Thr68、pCDC25C-Ser216protein and the clinicopathological parameters of breast cancerpatients. To explore its role in the development of breast cancer and the feasibility of theseproteins as therapeutic targets.Materials and MethodsCollected surgical specimens of292patients with breast cancer were used to maketissue microarray. Immunohistochemical technique was used to test pCHK2-Thr68andpCDC25C-Ser216protein expression in breast cancer and paracancerous tissues. Thecorrelations between protein expression and its clinical significance was analysed.Combining detection of pCHK2-Thr68and pCDC25C-Ser216protein was carried out toclarify the clinical significance in breast cancer. The correlation between the expression ofprotein and pathological type,histological grade, tumor size, lymph node metastasis andTNM staging was analysed.1.Using immunohistochemical technique to analyse pCHK2-Thr68expression inbreast cancer and paracancerous tissue and its clinical significance. The relationshipbetween protein expression in breast cancer and paracancerous tissue as well as therelationship between the clinicopathological parameters were analysed using the Pearson ’s χ2test or Fisher’s exact probability methods and multivariate analysis by logistic regression.2. Immunohistochemical technique was used to test the expression of pCDC25C-Ser216in breast cancer and paracancerous tissue. The expression of pCDC25C-Ser216protein differences and its clinical significance were explored. The distribution differenceof pCDC25C-Ser216expression between breast cancer and paracancerous tissue and therelationship between protein expression and clinicopathological parameters were analysedusing the Pearson ’s χ2test or Fisher’s exact probability methods. Logistic regression was used to implement multivariate analysis. McNemar test was used to analyse therelationship between paired breast cancer and paracancerous tissue.3.Combining detection of the expression of of pCHK2-Thr68and pCDC25C-Ser216proteins in breast cancer. The relationship of pCHK2-Thr68and pCDC25C-Ser216wasanalysed using Spearman correlation coefficient test. pCHK2-Thr68/pCDC25C-Ser216combining expression state was divided into four groups and the relationship between theexpression of four groups and clinical pathological parameters was analysed using Fisherexact probability methods.4. Applying the statistical analysis software SPSS18.0, all data were performedbilateral inspection,inspection level α=0.05ResultsDue to offchip and bad dyeing effection, the color reaction of pCHK2-Thr68andpCDC25C-Ser216can be observed in265cases of cancer tissues and33casesparacancerous tissue among292cases of breast cancer tissue microarray.1.Significant difference of the expression of pCHK2-Thr68protein in breast cancerand paracancerous tissue was observed, the expression in cancer tissues was higher thanthat of paracancerous tissues (20.38%and0, P=0.005). Increased expression ofpCHK2-Thr68was significantly correlated with Luminal B breast cancers(P=0.0065, OR=2.337). There was no significant correlation between the expression of pCHK2-Thr68andclinical staging T staging, N staging (the number of lymph node metastasis),pathologicaltype,histological grade, menopausal, HER2, ER, PR status and age.2.The expression of pCDC25C-Ser216protein localized in nucleus and cytoplasm,Almost all expressed in the nucleus with paracancerous tissue.Compared withparacancerous tissues, the expression of pCDC25C-Ser216protein in breast carcerincreased significantly(82.26%Vs24.24%, P=0.000). There was no consistent relationshipbetween the expression of pCDC25C-Ser216protein in carcer and paracanceroustissues(p=0.078).No significant correlation existed between the expression ofpCDC25C-Ser216protein and clinical pathologicalparameters.3.There was a positive correlation between expression of pCHK2-Thr68andpCDC25C-Ser216in breast cancer, the correlation efficient was0.137(p=0.026). ThepCHK2-Thr68/pCDC25C-Ser216expression status was divided into four groups, therewas no obvious correlation in four groups with clinical staging, T staging (tumor size), Nstaging (the number of lymph node metastasis), pathological type, histological grade, menopausal,HER2,ER,PR status, age and the approximate molecular type.ConclusionsThe study showed that: expression of pCHK2-Thr68and pCDC25C-Ser216proteinsin breast cancer was significantly higher than that in paracancerous tissues, the two proteinexpression were positively correlated. The expression of pCHK2-Thr68was significantlycorrelated with LuminalB breast cancer.DNA damage repair pathway proteins CHK2、CDC25C may play an important role in the occurrence and development of breast cancerand may be a potential clinical therapeutic target.